Azithromycin and clarithromycin: overview and comparison with erythromycin.

Area of Science:

• Pharmacology
• Microbiology
• Infectious Diseases

Background:

• Azithromycin and clarithromycin are FDA-approved erythromycin analogues.
• These macrolides inhibit protein synthesis by targeting the 50S ribosomal subunit.
• Resistance mutations in the binding site confer cross-resistance to all macrolides.

Purpose of the Study:

• To compare the in vitro and in vivo efficacy of azithromycin and clarithromycin against various pathogens.
• To evaluate the pharmacokinetic and pharmacodynamic properties of these new macrolides.
• To assess their potential for improved dosing regimens and patient compliance.

Main Methods:

• In vitro susceptibility testing against Gram-positive bacteria, H. influenzae, and atypical pathogens.
• Pharmacokinetic studies assessing tissue distribution and half-life.
• Comparison of dosing regimens and reported side effects with erythromycin.

Main Results:

• Clarithromycin shows higher in vitro activity against Gram-positives; azithromycin is less potent but active against H. influenzae.
• Both drugs are effective against respiratory and soft tissue infections, comparable to standard therapies.
• Azithromycin exhibits excellent tissue penetration and a long half-life, enabling novel dosing.
• Clarithromycin has a longer serum half-life and better tissue penetration than erythromycin, allowing twice-daily dosing.
• Both agents are active against unexpected pathogens like B. burgdorferi and M. avium complex.
• Gastrointestinal distress is less common with azithromycin and clarithromycin compared to erythromycin.

Conclusions:

• Azithromycin and clarithromycin offer superior pharmacokinetic profiles and improved dosing convenience over erythromycin.
• Their broad-spectrum activity and reduced side effects enhance patient compliance for various infections.
• Clarithromycin shows promise against atypical mycobacteria, while azithromycin offers effective treatment for C. trachomatis infections.
• Further clinical data will refine the roles of these new macrolides in infectious disease treatment.